OPINION

Gut Microbiota and Pancreatic Health: Etiological Implications and Therapeutic Opportunities

Nadine Carrier*

Translational Pancreatic Cancer Oncogenesis Group, Hospital Universitari Son Espases (HUSE), Spain

Introduction

The gut microbiota, a complex community of microorganisms residing in the gastrointestinal tract, plays a critical role in maintaining host health and homeostasis. Emerging evidence suggests that alterations in gut microbiota composition and function can influence the pathogenesis of various diseases, including pancreatic disorders. In recent years, research into the gut-pancreas axis has revealed intriguing connections between the gut microbiota and pancreatic health, shedding light on potential etiological mechanisms and therapeutic avenues [1].

This review explores the current understanding of gut microbiota-host interactions in the context of pancreatic diseases, highlighting their etiological implications and therapeutic opportunities. The gut microbiota comprises trillions of bacteria, archaea, viruses, fungi, and other microorganisms that colonize the intestinal mucosa. These microorganisms form a complex ecosystem that plays essential roles in nutrient metabolism, immune regulation, and protection against pathogens [2].

The composition and diversity of the gut microbiota are influenced by various factors, including diet, host genetics, age, medications, and environmental exposures. While there is considerable interpersonal variability in gut microbiota composition, certain bacterial taxa, such as Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria, are commonly found in the healthy human gut [3].

Mounting evidence suggests that dysbiosis, defined as an imbalance in gut microbiota composition and function, may contribute to the pathogenesis of pancreatic diseases, including pancreatic cancer, chronic pancreatitis, and pancreatic cysts. Several studies have reported differences in gut microbiota composition between patients with pancreatic diseases and healthy controls, suggesting potential etiological implications. For example, individuals with pancreatic cancer often exhibit reduced microbial diversity and alterations in specific bacterial taxa compared to healthy individuals [4].

Similarly, patients with chronic pancreatitis or pancreatic cysts may harbor distinct gut microbiota profiles indicative of intestinal dysbiosis. Gut microbiota dysbiosis can influence pancreatic health through multiple mechanisms, including modulation of immune responses, production of microbial metabolites, and alteration of mucosal barrier integrity. Dysbiotic gut microbiota may promote inflammation and oxidative stress in the pancreas, contributing to the development and progression of pancreatic diseases [5].

Additionally, gut microbial metabolites, such as short-chain fatty acids (SCFAs), bile acids, and secondary bile acids, can impact pancreatic function and carcinogenesis through their effects on cellular signaling pathways and gene expression. Furthermore, gut microbiota dysbiosis may contribute to systemic inflammation and metabolic dysfunction, which are known risk factors for pancreatic diseases. Chronic low-grade inflammation, driven by gut-derived microbial products and pro-inflammatory cytokines, can promote pancreatic fibrosis and tumorigenesis [6].

Moreover, alterations in gut microbiota composition may influence host metabolism and insulin sensitivity, affecting pancreatic β-cell function and predisposing individuals to metabolic disorders such as obesity and type 2 diabetes, which are risk factors for pancreatic cancer and chronic pancreatitis. Modulating gut microbiota composition and function represents a promising therapeutic approach for the prevention and treatment of pancreatic diseases [7].

Strategies aimed at restoring eubiosis (healthy microbial balance) and targeting dysbiotic microbial communities hold potential for mitigating pancreatic inflammation, improving pancreatic function, and reducing

Received 25-Jan-2024 Manuscript No ipp-24-19032 **Editor Assigned** 27-Jan-2024 PreQC No ipp-24-19032(PQ) **Reviewed** 10-Feb-2024 QC ipp-24-19032 **Revised** 15-Feb-2024 Manuscript No ipp-24-19032(R) **Published** 22-Feb-2023 DOI 10.35841/1590-8577-25.1.846

Correspondence Nadine Carrier,
Translational Pancreatic Cancer Oncogenesis Group,
Hospital Universitari Son Espases (HUSE), Spain
E-mail Nadine@spain.edu

Citation: Carrier N. Gut Microbiota and Pancreatic Health: Etiological Implications and Therapeutic Opportunities. JOP. J Pancreas. (2024) 25:846

disease progression. Probiotics, live microorganisms with beneficial health effects, and prebiotics, nondigestible fibers that promote the growth of beneficial bacteria, have been investigated as potential interventions for modulating gut microbiota composition and promoting pancreatic health [8].

Additionally, fecal microbiota transplantation (FMT), the transfer of fecal microbiota from healthy donors to recipients, has shown promise in restoring gut microbiota diversity and function in various gastrointestinal disorders, including inflammatory bowel disease and Clostridioides difficile infection. While FMT has not been extensively studied in the context of pancreatic diseases, preliminary evidence suggests that it may have therapeutic potential in modulating gut microbiota dysbiosis and attenuating pancreatic inflammation [9].

Furthermore, dietary interventions targeting gut microbiota composition, such as fiber-rich diets, Mediterranean diets, and plant-based diets, have been associated with beneficial effects on pancreatic health. These diets promote the growth of beneficial bacteria and enhance microbial diversity, thereby reducing inflammation and oxidative stress in the pancreas. Future research aimed at elucidating the mechanisms underlying the effects of dietary interventions on gut microbiota-host interactions and pancreatic health is warranted to optimize therapeutic strategies for pancreatic diseases [10].

Conclusion

The gut microbiota plays a pivotal role in pancreatic health, with dysbiosis implicated in the pathogenesis of pancreatic diseases. Understanding the etiological implications of gut microbiota dysbiosis and its impact on pancreatic inflammation, fibrosis, and carcinogenesis provides valuable insights into disease mechanisms and therapeutic opportunities. Modulating gut microbiota composition and function through probiotics, prebiotics, FMT, and dietary interventions holds promise for preventing and treating pancreatic diseases. Continued research efforts aimed at unraveling the complex interactions between the gut microbiota and the pancreas are essential for developing effective therapeutic strategies to improve patient outcomes in pancreatic diseases.

References

1. Del Chierico F, Rapini N, Deodati A, Matteoli MC, Cianfarani S, Putignani L. Pathophysiology of type 1 diabetes and gut microbiota role. Int J Mol Sci. 2022;23(23):14650. [PMID: 36498975]

2. Di Vincenzo F, Nicoletti A, Negri M, Vitale F, Zileri Dal Verme L, et al. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics (Basel). 2023;12(6):1068. [PMID: 37370387]

3. Lau HC, Kranenburg O, Xiao H, Yu J. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol. 2020;17(4):203-22. [PMID: 32099092]

4. Chen Y, Wang J, Zou L, Cao H, Ni X, Xiao J. Dietary proanthocyanidins on gastrointestinal health and the interactions with gut microbiota. Crit Rev Food Sci Nutr. 2023;63(23):6285-308. [PMID: 35114875]

5. Georgescu D, Caraba A, Ionita I, Lascu A, Hut EF, Dragan S, et al. Dyspepsia and gut microbiota in female patients with postcholecystectomy syndrome. Int J Womens Health. 2022:41-56. [PMID: 35136356]

6. Shin JH, Bozadjieva-Kramer N, Shao Y, Lyons-Abbott S, Rupp AC, Sandoval DA, et al. The gut peptide Reg3g links the small intestine microbiome to the regulation of energy balance, glucose levels, and gut function. Cell Metab. 2022;34(11):1765-78. [PMID: 36240758]

7. Yang J, He Q, Lu F, Chen K, Ni Z, Wang H, et al. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma. Gut Microbes. 2023;15(1):2201159. [PMID: 37089022]

8. Skalny AV, Aschner M, Lei XG, Gritsenko VA, Santamaria A, Alekseenko SI, et al. Gut microbiota as a mediator of essential and toxic effects of zinc in the intestines and other tissues. Int J Mol Sci. 2021;22(23):13074. [PMID: 34884881]

9. Liu JL, Segovia I, Yuan XL, Gao ZH. Controversial roles of gut microbiota-derived short-chain fatty acids (SCFAs) on pancreatic β-cell growth and insulin secretion. Int J Mol Sci. 2020;21(3):910. [PMID: 32019155]

10. Wang J, Jiang M, Hu Y, Lei Y, Zhu Y, Xiong H, et al. Lactulose regulates gut microbiota dysbiosis and promotes short-chain fatty acids production in acute pancreatitis patients with intestinal dysfunction. Biomed Pharmacother. 2023;163:114769. [PMID: 37116350]

Citation: Carrier N. Gut Microbiota and Pancreatic Health: Etiological Implications and Therapeutic Opportunities. JOP. J Pancreas. (2024) 25:846